Fulgent Genetics
FLGT
24.12
-0.66
-2.66%
Fulgent Genetics
US · FLGT
#3667 by market cap
Listed 2016
24.12
-0.66
-2.66%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.6 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 56.27% -1.61pp
- Institutions
- 183 +2
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund39.07%
Individual/Insider38.71%
Hedge Fund10.38%
Public Company4.20%
Private Company1.42%
Family Office/Trust0.81%
Government Pension Fund0.25%
Insurance Company0.15%
Other5.01%
Top holders as of 2026-09-01
Ming Hsieh
31.76% · 8.87M sh
BlackRock
8.73% · 2.44M sh
Acadian Asset Management LLC
3.90% · 1.09M sh
Hanlin Gao
3.52% · 984.47K sh
Jacobs Levy Equity Management Inc
2.80% · 782.12K sh
Vanguard Capital Management, LLC
2.74% · 765.87K sh
JPMorgan Chase & Co.
2.61% · 717.22K sh
Diametric Capital, LP
2.50% · 697.78K sh
Columbia Management Investment Advisers, LLC
2.40% · 670.08K sh
Dimensional Fund Advisors
2.31% · 646.63K sh
Jian Xie
2.06% · 576.38K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 12 buys · 38 sells
| Name | Role | Stake |
|---|---|---|
| Ming Hsieh | Chairperson & CEO | 31.76% |
| Hanlin Gao | Chief Scientific Officer & Lab Director | 3.52% |
| Jian Xie | Chief Operating Officer | 2.06% |
| Paul Kim | Chief Financial Officer | 1.27% |
| Linda Dong | Independent Director | 0.04% |
| Michael Nohaile | Independent Director | 0.03% |
| Regina Groves | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,748 | $20.22 |
| 2026-10-25 | Hanlin Gao | Chief Scientific Officer & Lab Director | Sale to Issuer | -1,645 | $20.22 |
| 2026-10-25 | Jian Xie | Chief Operating Officer | Sale to Issuer | -4,361 | $20.22 |
| 2026-09-01 | Hanlin Gao | Chief Scientific Officer & Lab Director | Open Market Disposition | -1,673 | $19.66 |
| 2026-09-01 | Jian Xie | Chief Operating Officer | Open Market Disposition | -2,127 | $19.66 |
| 2026-08-31 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,087 | $19.59 |
| 2026-08-31 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -4,392 | $19.59 |
| 2026-08-26 | Hanlin Gao | Chief Scientific Officer & Lab Director | Open Market Disposition | -939 | $19.91 |
| 2026-08-26 | Jian Xie | Chief Operating Officer | Open Market Disposition | -1,193 | $19.91 |
| 2026-08-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -1,168 | $19.81 |
| 2026-08-25 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -2,949 | $19.81 |
| 2026-07-25 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,747 | $19.67 |
| 2026-07-25 | Hanlin Gao | Chief Scientific Officer & Lab Director | Sale to Issuer | -1,645 | $19.67 |
| 2026-07-25 | Jian Xie | Chief Operating Officer | Sale to Issuer | -4,361 | $19.67 |
| 2026-06-01 | Hanlin Gao | Chief Scientific Officer & Lab Director | Open Market Disposition | -1,688 | $17.89 |
| 2026-06-01 | Jian Xie | Chief Operating Officer | Open Market Disposition | -2,146 | $17.89 |
| 2026-05-31 | Paul Kim | Chief Financial Officer | Sale to Issuer | -2,087 | $18.09 |
| 2026-05-31 | Ming Hsieh | Chairperson & CEO | Sale to Issuer | -4,392 | $18.09 |
| 2026-05-26 | Hanlin Gao | Chief Scientific Officer & Lab Director | Open Market Disposition | -945 | $17.60 |
| 2026-05-26 | Jian Xie | Chief Operating Officer | Open Market Disposition | -1,201 | $17.60 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Fulgent Genetics discussion 0 comments